FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.
FDA okayed the first treatment for chronic sialorrhea, or excessive drooling, in adult patients.
The agency cleared the supplemental Biologics License Application (sBLA) for incobotulinumtoxinA (Xeomin, Merz North America), the first and only neurotoxin with this approved indication in the US, according to Merz.
“We are excited about the FDA’s approval of Xeomin for chronic sialorrhea, as this represents a significant milestone in addressing a condition that affects more than 600,000 adults in the U.S. In the past, sialorrhea has been difficult to treat often requiring a comprehensive treatment plan; this approval may help provide a more simplified treatment option,” Kevin O’Brien, vice president and US head of neurosciences for Merz North America, told FormularyWatch.
Related: FDA approves first cannabis-based drug for rare forms of epilepsy
O’Brien said the wholesale acquisition cost is not yet available. The drug, however, is available immediately.
Sialorrhea is a common symptom among patients who suffer from neurological disorders including Parkinson's disease, amyotrophic lateral sclerosis (ALS), and cerebral palsy (CP), as well as those who have experienced a stroke.
Related: FDA reviewing safety of Parkinson’s drug
FDA granted this application a priority review designation upon acceptance. Xeomin, first approved by FDA in 2010 for the treatment of cervical dystonia and blepharospasm (in patients previously treated with onabotulinumtoxinA) in adult patients, now has 4 neurological indications.
FDA’s approval of Xeomin sialorrhea is based on a phase 3, randomized, double-blind, trial of 184 patients. A statistically significant improvement was observed in change in unstimulated salivary flow rate (uSFR) and Global Impression of Change Scale (GICS), both at week 4 as compared to baseline pre-injection for subjects administered 100 U incobotulinumtoxinA versus placebo.
Read more: New Parkinson's drug, 2 others approved
Get the latest industry news, event updates, and more from Managed healthcare Executive.
PBM-Offered Genomics Testing Could Reshape Prescribing of Medications
July 25th 2025Two PBMs, True Rx Health Strategies and Capital Rx, are using pharmacogenomics — how a person’s DNA affects their response to medications — to reduce the trial-and-error of prescribing medications, saving employers and patients time and money.
Read More
FDA Extends Review of Blenrep Combinations in Multiple Myeloma
July 24th 2025Last week, an FDA advisory committee against the risk-benefit profile of Blenrep in combination with other therapies. Regulators and reviewers were concerned about the ocular side effects and dosing and tolerability. The new action date is Oct. 23, 2025.
Read More
Sarepta to Pause Shipments of the Gene Therapy Elevidys
July 22nd 2025Sarepta officials said the temporary halt in shipments was done to maintain a productive working relationship with regulators while they address a safety labeling update about the risk of acute liver disease related to Elevidys.
Read More